Fig. 5

Transcriptomic changes between myeloid-T and myeloid-B. a Pathway analysis of differentially methylated promoter CpG probes (FDR <0.1 and delta beta value >0.15) between myeloid-B and myeloid-T phenotypes showing significant enrichment of T cell receptor pathways. P value was calculated by Fisher’s exact test and FDR was calculated by Benjamini–Hochsberg method. b Starburst plot integrating analysis of gene expression and promoter methylation. Red dots represent promoter CpG probes with significantly differential methylation that are also associated with significant differences in expression between myeloid-B and myeloid-T. c Log2 fold differences of transcription levels of genes that were significantly different between myeloid-B and myeloid-T phenotypes and were associated with significant promoter methylation differences. P value was calculated by Wald test and adjusted for multiple testing by Benjramini–Hochberg method. d Motif enrichment analysis of promoter CpG probes differentially methylated between the two phenotypes showing significant enrichment of IRF8 and IRF4 recognition motifs. P value was calculated by Wilcoxon rank-sam test. e Log2 fold differences of transcription levels of key downstream target genes of IRF8 and IRF4 between myeloid-B (My-B) and myeloid-T (My-T) phenotypes. P value was calculated by Wald test and adjusted for multiple testing by Benjramini–Hochberg method. f Gene set enrichment analysis (GSEA) comparing gene expression data from RNA sequencing between myeloid-B and myeloid-T phenotypes showing significant enrichment of B cell receptor (BCR) and NFκB pathways in myeloid-B MPAL. The method of estimating nominal P value and FDR adjustment is described elsewhere ⁵²